Format

Send to

Choose Destination
Drugs. 2016 May;76(8):901-5. doi: 10.1007/s40265-016-0579-y.

Ixekizumab: First Global Approval.

Author information

1
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Abstract

Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.

PMID:
27098317
DOI:
10.1007/s40265-016-0579-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center